IPSC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IPSC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-13), Century Therapeutics's share price is $3.13. Century Therapeutics's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $3.06. Hence, Century Therapeutics's Price to Tangible Book Ratio of today is 1.02.
The historical rank and industry rank for Century Therapeutics's Price-to-Tangible-Book or its related term are showing as below:
During the past 5 years, Century Therapeutics's highest Price to Tangible Book Ratio was 2.20. The lowest was 0.99. And the median was 1.08.
A closely related ratio is called PB Ratio. As of today, Century Therapeutics's share price is $3.13. Century Therapeutics's Book Value per Sharefor the quarter that ended in Dec. 2023 was $3.06. Hence, Century Therapeutics's P/B Ratio of today is 1.02.
The historical data trend for Century Therapeutics's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Century Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Price-to-Tangible-Book | - | - | 2.20 | 0.99 | 1.08 |
Century Therapeutics Quarterly Data | ||||||||||||||||||
Jun19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Price-to-Tangible-Book | Get a 7-Day Free Trial | 0.99 | 0.74 | 0.76 | 0.54 | 1.08 |
For the Biotechnology subindustry, Century Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Century Therapeutics's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Century Therapeutics's Price-to-Tangible-Book falls into.
Century Therapeutics's price-to-tangible-book ratio for today is calculated as:
Price to Tangible Book | = | Share Price | / | Tangible Book per Share (Q: Dec. 2023 ) |
= | 3.13 | / | 3.062 | |
= | 1.02 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price to Tangible Book | = | Market Cap | / | Tangible Equity | ||||
= | Market Cap | / | (Total Stockholders Equity | - | Preferred Stock | - | Intangible Assets) |
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Thank you for viewing the detailed overview of Century Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.
Luis Borges | officer: Chief Scientific Officer | TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080 |
Timothy P Walbert | director | 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062 |
Daphne Quimi | director | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Versant Venture Capital Vi, L.p. | 10 percent owner | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Joseph Jimenez | director | ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607 |
Eli Casdin | director | 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019 |
Cynthia M Butitta | director | 3165 PORTER DRIVE, PALO ALTO CA 94304 |
Kimberly Blackwell | director | C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018 |
Rizzuto Carlo | director | ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104 |
Alessandro Riva | director | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
Hyam Levitsky | officer: President of R&D | C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010 |
Adrienne Farid | officer: Chief Operations Officer | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
Gregory Russotti | officer: Chief Technology Officer | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
Osvaldo Flores | officer: Chief Executive Officer | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
Douglas Carr | officer: VP of Finance and Operations | C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 06-16-2022
By sperokesalga sperokesalga • 04-12-2023
By Marketwired • 09-26-2023
By Stock market mentor Stock market mentor • 01-04-2023
By GuruFocusNews GuruFocusNews • 06-21-2022
By GuruFocus Research • 11-09-2023
By Value_Insider Value_Insider • 11-11-2022
By GuruFocusNews GuruFocusNews • 07-04-2022
By GuruFocusNews GuruFocusNews • 06-25-2022
By Stock market mentor Stock market mentor • 02-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.